MDRX · As filed with the SEC
Veradigm income statement, by quarter
The statement as Veradigm presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD
| USD | Q4 2024 3 months ended Dec 31, 2024 | Q4 2022 3 months ended Dec 31, 2022 | Q3 2022 3 months ended Sep 30, 2022 | Q2 2022 3 months ended Jun 30, 2022 | Q1 2022 3 months ended Mar 31, 2022 | Q4 2021 3 months ended Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | 156,212,000 | 151,922,000 | 150,898,000 | 142,672,000 | 157,222,000 |
| Payer & Life Science | — | — | 29,111,000 | 31,959,000 | 24,007,000 | — |
| Provider | — | — | 122,811,000 | 118,939,000 | 118,665,000 | — |
| Provider | — | — | 57,252,000 | 58,326,000 | 57,017,000 | — |
| Payer & Life Science | — | — | 11,234,000 | 13,090,000 | 12,174,000 | — |
| Cost of revenue | — | 69,361,000 | 68,486,000 | 71,416,000 | 69,191,000 | 73,822,000 |
| Gross profit | — | 86,851,000 | 83,436,000 | 79,482,000 | 73,481,000 | 83,400,000 |
| Selling, general and administrative expenses | — | 43,651,000 | 32,518,000 | 59,847,000 | 41,318,000 | 24,634,000 |
| Research and development | — | 26,981,000 | 23,681,000 | 22,750,000 | 23,420,000 | 21,421,000 |
| Asset impairment charges | — | 3,945,000 | 0 | 0 | — | 2,000 |
| Amortization of intangible and acquisition-related assets | — | 21,736,000 | 2,236,000 | 2,241,000 | 2,171,000 | 2,192,000 |
| Income (loss) from operations | — | (9,462,000) | 25,001,000 | (5,356,000) | 6,572,000 | 35,151,000 |
| Interest expense | — | (1,085,000) | (1,246,000) | (1,887,000) | (2,136,000) | (3,457,000) |
| Other income (expense), net | — | 1,464,000 | 1,655,000 | 2,133,000 | 12,000 | 63,289,000 |
| Gain (loss) on sale of businesses, net | — | — | 0 | — | — | 7,000 |
| Equity in net income (loss) of unconsolidated investments | — | 155,000 | (617,000) | (207,000) | (398,000) | 2,078,000 |
| Income (loss) from continuing operations before income taxes | — | (8,928,000) | 24,793,000 | (5,317,000) | 4,050,000 | 91,913,000 |
| Income tax benefit (provision) | — | (17,952,000) | (13,868,000) | (8,579,000) | 14,421,000 | (17,450,000) |
| Income (loss) from continuing operations, net of tax | — | — | 10,925,000 | 3,262,000 | 18,471,000 | — |
| Income (loss) from discontinued operations | — | — | (434,000) | (3,797,000) | (5,021,000) | — |
| Loss from discontinued operations | — | 628,000 | — | — | — | 444,000 |
| Loss on sale of discontinued operations | — | 0 | 5,174,000 | 2,765,000 | 0 | 0 |
| Income tax effect on discontinued operations | — | (303,000) | (1,137,000) | (66,256,000) | 9,407,000 | (1,379,000) |
| Loss from discontinued operations, net of tax | — | 325,000 | 3,603,000 | (67,288,000) | 4,386,000 | (935,000) |
| Net income (loss) | — | (26,555,000) | 14,528,000 | (64,026,000) | 22,857,000 | 73,528,000 |
| Basic | ||||||
| Continuing operations | — | (0.25) | 0.1 | 0.03 | 0.16 | 0.62 |
| Discontinued operations | — | 0 | 0.03 | (0.59) | 0.04 | 0 |
| Net basic earnings (loss) per common share | — | (0.25) | 0.13 | (0.56) | 0.2 | 0.62 |
| Diluted | ||||||
| Continuing operations | — | (0.25) | 0.09 | 0.03 | 0.14 | 0.58 |
| Discontinued operations | — | 0 | 0.03 | (0.57) | 0.03 | (0.01) |
| Net income (loss) per share - Diluted | — | (0.25) | 0.12 | (0.54) | 0.17 | 0.57 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.